drugset / Trial / NCT01358227

A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors

NCT01358227

Phase 1 Completed 26 enrolled Proacta, Incorporated
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the side effects and best weekly dose of PR104 in patients with advanced solid tumors.

Timeline

Start
2006-12
Primary completion
2009-12
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject PR104 Small molecule Intravenous